Best Genomics Companies in Texas, United States
The 118 best Genomics companies in Texas, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Caris Life Sciences.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Texas
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Caris Life Sciences 🦄 Developer of panomic disease profiling technologies for cancer precision medicine 78Moat top 15%Funding top 17%Product top 19%Market top 28% All 9 signals ▾Moattop 15% Fundingtop 17% Producttop 19% Markettop 28% Innovationtop 38% Growthtop 40% Newstop 43% Techtop 44% Globaltop 46% Moat: Editorial + unicorn rating 9/10 · Unicorn Funding: Raised $1.1B across 6 rounds · 6 rounds over 9 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 78/100 | $1.1B | 14 mo ago | 1,339 | — | WordPress Site EditorCart FunctionalityWordPress+19 | — | — |
| 2 | Lexicon Pharmaceuticals Developer of small molecule drugs for diffrent health diseases 76Funding top 20%Patents top 24%Talent top 28%Growth top 30% All 11 signals ▾Fundingtop 20% Patentstop 24% Talenttop 28% Growthtop 30% Techtop 35% Innovationtop 40% Markettop 41% Fin. healthtop 41% Moattop 44% Newstop 45% Globalbottom 44% Funding: Raised $381M across 9 rounds · 9 rounds over 28 yrs (0.3/yr) Patents: 1,211 patents matched (strict assignee match) · 94 filings since 2022 vs 219 in 2017-21 rank vs industry peers · Fliar Intelligence Index 76/100 | $381M | 4 mo ago | 135 135 → 284 (+110%) | Ivan Cheung Board of Directors | DrupalApple iCloud MailPHP+31 | 1,211 patents Patents concentrated in chemistry & materials | — |
| 3 | Everlywell 🦄 Provider of home-based diagnostic tests for the detection of various diseases | $330M | 65 mo ago | 614 | Julia Cheek Founder & CEO | ContentfulChakra UIReact+31 | — | — |
| 4 | Bellicum Developer of T cell therapies for the treatment of cancer and chronic infectious diseases | $138M | 141 mo ago | 108 | — | DrupalApple iCloud MailMicrosoft 365+20 | — | — |
| 5 | Aspira Women's Health Provider of diagnostic solution for ovarian malignancy in women 32Funding top 29%Tech top 46%Market bottom 46%Fin. health bottom 36% All 7 signals ▾Fundingtop 29% Techtop 46% Marketbottom 46% Fin. healthbottom 36% Growthbottom 35% Globalbottom 30% Newsbottom 21% Funding: Raised $96.7M across 8 rounds · 8 rounds over 16 yrs (0.5/yr) Tech: 36 technologies across 4/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 32/100 | $97M | 9 mo ago | 85 85 → 60 (-29%) | — | WordPressApple iCloud MailMySQL+25 | — | 2 partnerships |
| 6 | Embark Veterinary Proivder of DNA test kits for dogs that enable dog owners to provide better pet care | $94M | 58 mo ago | 141 | Amish Desai Chief Executive Officer | ShopifyWordPressSentry+53 | 20 patents Canine genetic testing platforms for pigmentation and ancestry phenotype prediction | — |
| 7 | Lasergen Analytical and clinical lab technologies providing insights and solutions for great science | $85M | 123 mo ago | 6,001 | — | — | 67 patents Photocleavable nucleotides and labels for advanced DNA sequencing and antigen assays | — |
| 8 | Asuragen Molecular diagnostics and genetics company advancing precision medicine in oncology | $80M | 80 mo ago | 114 114 → 101 (-11%) | — | WordPressApple iCloud MailMicrosoft 365+19 | 351 patents Detecting and analyzing repeat-rich nucleic acids and miRNA biomarkers for diagnostics. | — |
| 9 | OncoVista Developer of therapeutics and diagnostics for cancer | $65M | 127 mo ago | 3 | Alex Weis CEO | — | — | — |
| 10 | Med fusion Precision medicine solutions, advanced diagnostics, and clinical trial support | $61M | 149 mo ago | 414 | — | WordPressAdobe Experience ManagerMySQL+20 | — | — |
| 11 | Endocare Provider of cancer diagnostic and therapeutic instruments | $53M | 228 mo ago | 120 | — | — | 193 patents Cryogenic and microwave ablation devices for minimally invasive surgical tumor treatment | — |
| 12 | Othram Provider of genomic services for forensic labs | $33M | 28 mo ago | 22 | David Mittelman Co-Founder & CEO | Cart FunctionalityShopifyApple iCloud Mail+23 | 8 patents Privacy-preserving genomic data management and molecular metadata handling | — |
| 13 | Ambion Provider of RNA extraction reagents and products | $10M | 194 mo ago | 300 | — | — | 95 patents RNA extraction, preservation, and analysis technologies for research and diagnostic applications. | — |
| 14 | Bio Developer of therapeutics for the treatment of cancer | $10M | 24 mo ago | 10 | — | — | — | — |
| 15 | Lantern Pharma Developing drug and companion diagnostics for multi-drug resistant cancers | $7M | 53 mo ago | 23 23 → 30 (+30%) | Panna Sharma Chief Executive Officer | WebflowApple iCloud MailGoogle Workspace+13 | — | 2 job openings · 1 launch |
| 16 | GenetiVision Provider of a research and technologies platform in Drosophila transgenesis | $6M | 45 mo ago | — | Rui Chen Co-Founder | — | — | — |
| 17 | Bacterial Barcodes Provides solutions to track hospital-acquired infections (HAI) and for environmental control for product… | $6M | 280 mo ago | — | Mimy Healy Ex-CEO and President | — | 4 patents Rapid bacterial detection using repetitive DNA primers and transcription‑based nucleic acid amplification | — |
| 18 | AMBiotech Chemically modified nucleic acids as affinity reagents | $6M | 96 mo ago | 7 | — | — | — | — |
| 19 | PHDx Solution for detection of diseases in patients | $6M | 95 mo ago | — | Jim Canfield CEO & President | — | — | — |
| 20 | Seralogix Streamlining preclinical research with innovative technology and solutions for enhanced results | $5M | 123 mo ago | — | Kenneth Drake Founder/CEO | — | — | — |
| 21 | Luna Genetics Developer of a non-invasive pre-natal diagnostic test | $4M | 54 mo ago | 15 | Philip Reilly Co-Founder | — | — | — |
| 22 | MolecularMatch Provider of clinical intelligence platform for precision oncology and immunotherapy | $4M | 142 mo ago | 6 | — | Apache HTTP ServerGoogle Font APIMailChimp+5 | 2 patents AI-driven genomic data analysis for personalized therapeutic recommendations | — |
| 23 | Wellnicity Provider of personalized supplement and diet recommendations based on biochemical analysis | $4M | 100 mo ago | 2 | — | — | — | — |
| 24 | Genprex Developer of therapeutics to treat cancer at molecular level | $3M | 71 mo ago | 28 28 → 23 (-18%) | — | WordPressMySQLPHP+21 | 12 patents Targeted gene‑therapy vectors and nucleic‑acid treatments for specific cancers | — |
| 25 | AptamiR Therapeutics Developer of microRNA-targeted therapeutics to treat human obesity | $3M | 117 mo ago | — | Marc Thibonnier Founder | — | — | — |
| 26 | SpeciCare Cancer care management platform | $2M | 73 mo ago | 13 | Ken Dixon Founder | WordPressMySQLPHP+27 | — | 2 partnerships |
| 27 | Twister Biotech Developer of gene therapies for rare cancers and autoimmune diseases | $2M | 33 mo ago | 3 | Lynn Zechiedrich Founder & CEO | — | — | — |
| 28 | Magnolia Diagnostics Diagnostic lab providing fast, accurate results for providers and patients | $938K | 101 mo ago | 21 | Kelly Bains Co-Founder | — | — | — |
| 29 | LC Sciences Provider of products and services for genomics and proteomics research | $572K | 203 mo ago | 18 | — | Node.jsZohoVue.js+8 | — | — |
| 30 | RedVault Biosciences Innovating genomic medicine through technology to improve human health and well-being | $524K | 32 mo ago | — | Michael Metzker Founder | — | — | — |
| 31 | CancerGene Connect Provider of SaaS based genetic screening for cancer risk assesment | $300K | 116 mo ago | 7 | — | — | — | — |
| 32 | MultiVir Developer of gene therapies to treat cancer | $270K | 95 mo ago | — | Robert Sobol CEO | — | 45 patents Patents concentrated in chemistry & materials | — |
| 33 | Arpeggi Develops solutions for genome sequencing services | $195K | 160 mo ago | — | — | — | — | — |
| 34 | ViaGen Provider of animal genetic preservation and cloning services | $150K | 185 mo ago | 28 | Blake Russell CEO | — | 7 patents Patents concentrated in health & consumer products | — |
| 35 | Aperture Bio Developer of in-vitro diagnostics for drug-resistant bacterial infections | $100K | 32 mo ago | — | Kevin Kuykendall CEO | — | — | — |
Top 12 Genomics companies in Texas
#1
Public · The Woodlands, Texas · founded 1995 · 135 employees$381.3Mraised▾
Developer of small molecule drugs for diffrent health diseases. It uses gene trapping and gene targeting technologies to discover new drug targets and develop small molecule drugs across therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
- Feb 2026Post IPO$55.7M
- Aug 2022Post IPO$42.9M
- Mar 2017Post IPO$10.5M
- Dec 2014Post IPO$4.7M
#2
Public · Irving, Texas · founded 1996 · 1339 employees$1.1Braised▾
Developer of panomic disease profiling technologies for cancer precision medicine. The company leverages artificial intelligence (AI) and machine learning algorithms. Leveraging our proprietary AI analytics engine, DEAN for advancing the oncology precision medicine platform. It offers tumor profiling services, a complete molecular blueprint, and guiding personalized cancer treatment.
- Apr 2025Series D$168M
- Jan 2023Conventional Debt—
- May 2021Series D$830M
- Oct 2020Conventional Debt$75M
#3
Public · Austin, Texas · founded 1993 · 85 employees$96.7Mraised▾
Provider of diagnostic solution for ovarian malignancy in women. It offers products OVA1 and OVERA to detect the risk of ovarian cancer for patients. It also offers its flagship product for the detection of risk heredity breast and ovary cancer; ASPiRA GenetiXSM testing which offers comprehensive genetic testing options with a gynecologic focus.
- Sep 2025Post IPO$3M
- Mar 2025Post IPO$1.4M
- Jun 2024Post IPO$1.9M
- Jul 2020Post IPO$11M
#4
Series B · Houston, Texas · founded 2018 · 22 employees$33.2Mraised▾
Provider of genomic services for forensic labs. The company enables proprietary genomic biomarkers to analyze the genome profile for investigations and research purposes. They also recover DNA from small samples using amplification. They offer solutions for trait identification and gene relatedness profile by comparing the genome sequence to find ancestry lineage, hair color, height, gene-based relatives, and more.
- Feb 2024Series B$22.1M
- Sep 2021Series B$18M
- May 2020Series A$4.6M
- Apr 2019Grant (prize money)$10K
#5
Public · Houston, Texas · founded 2000 · 10 employees$10.3Mraised▾
Developer of therapeutics for the treatment of cancer. The company has developed a proprietary neutral-lipid delivery technology for delivering drugs which include Prexigebersen (Liposomal Grb-2) for patients with AML, CML, breast, and ovarian cancers and BP1002 (Liposomal Bcl2) is being studied for Follicular Lymphoma and other forms of Non-Hodgkin’s Lymphoma.
- Jun 2024Post IPO$4M
- Jan 2019Post IPO$1.7M
- Sep 2018Post IPO$1.5M
- Aug 2013Post IPO—
#6
Funding Raised · Austin, Texas · founded 2014 · 614 employees$330Mraised▾
Provider of home-based diagnostic tests for the detection of various diseases. The company offers diagnostic tests kits for monitoring health and wellness. Users can book tests for cardiovascular health, food sensitivity, women's fertility, and health, metabolism, inflammation, and many more. The prescription is provided by the doctors for the tests based on the state's regulation.
#7
Series B · Austin, Texas · founded 2015 · 141 employees$94.3Mraised▾
Provider of DNA test kits for dogs that enable dog owners to provide better pet care. The test tracks more than 200,000 genetic markers. The test analyzes the dog's ancestry and provides an overview of both genetic disease risk and heritable traits so the owners can understand their dog’s health plans for the future. It also provides an app for dog owners to book an appointment and invite the Embark team to their homes to learn more about the test kit.
- Jul 2021Series B$75M
- Apr 2019Series A$12.9M
- Jul 2018Conventional Debt$1.5M
- Jul 2017Series A$4.5M
#8
Public · Houston, Texas · founded 2004 · 108 employees$137.5Mraised▾
Bellicum is a developer of T cell therapies for the treatment of cancer and chronic infectious diseases. The company is developing CAR-T and TCR-based T cell therapies. Its drug pipeline consists of BPX-501, an adjunct T-cell therapy for pediatric genetic disease (eg- SCID) and hematologic cancer; BPX-701, a T cell receptor (TCR)-based therapy for the treatment of solid tumours expressing preferentially-expressed antigen in melanoma.
- Sep 2014Series C$94.4M
- Jan 2014Series B$14.7M
- Apr 2013Grant (prize money)$1.2M
- Mar 2012Series B$20M
#9
Acquired · Austin, Texas · founded 2006 · 114 employees$80Mraised▾
Molecular diagnostics and genetics company advancing precision medicine in oncology. They are dedicated to improving patient outcomes through innovative molecular diagnostic solutions. They specialize in developing and commercializing cutting-edge testing kits and services for inherited genetic disorders and cancer. Their portfolio includes a range of AmplideX genetics assay kits for inherited disorders and QuantideX qPCR kits for precision oncology. They offer molecular quality controls and OEM services. They leverage enabling technologies, assay chemistries, and bioinformatics to drive product development. They provide genetic testing solutions, including carrier screening. They are committed to advancing cancer care with precision oncology solutions, supporting research with targeted detection of molecular mutations. They offer diagnostic tests to monitor chronic myeloid leukemia. They provide resources, publications, and disease information. They operate in EMEA, providing solutions to European customers in genetics and oncology.
- Sep 2019Grant (prize money)$182.4K
- Sep 2019Grant (prize money)$227.1K
- Sep 2019Grant (prize money)$229.5K
- Jun 2019Grant (prize money)—
#10
Acquired · Houston, Texas · founded 2002 · 6001 employees$85Mraised▾
Analytical and clinical lab technologies providing insights and solutions for great science. The company delivers a comprehensive suite of instruments, software, and services to empower laboratories across diverse sectors. These include chemical analysis, life sciences, and diagnostics. The company offers analytical instruments, lab supplies, and instrument repair. It also provides software and informatics solutions for genomics and lab management. The company serves industries like biopharma, cancer research, environmental, food and beverage testing, and clinical diagnostics. The company provides training, consulting, and compliance services. The company's solutions support research, development, and quality control. The company offers e-commerce, order tracking, and technical support. The company focuses on innovation and sustainability.
- Mar 2016PE$80M
- Aug 2011Series A$5M
#11
Acquired · Austin, Texas · founded 1996 · 120 employees$53.1Mraised▾
Endocare provides cancer diagnostic and therapeutic instruments. The company offers an integrated biplane ultrasound that helps physicians with precise color Doppler visualization for detection of the tumor. The company also offers surgical instruments for cryopreserving the cancer cells and software for planning the surgery.
- May 2007Series B$7M
- Oct 2006Series B$16M
- Mar 2005Series B$15.6M
- Series B$14.5M
#12
Public · San Antonio, Texas · founded 2004 · 3 employees$65Mraised▾
Developer of therapeutics and diagnostics for cancer. The company identifies specific biomarkers in the bloodstream carried by CTCs to detect metastatic tumors. This allows an oncologist the unique ability to develop personalized cancer treatments. The company has developed a drug candidate called Cordycepin (OVI-123) for refractory leukemia.
- Nov 2015PE—
- Nov 2010PE$65M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Texas is moving
A read on the academic research around Bioinformatics in Texas — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 646 papers.
MD Anderson and UT Southwestern lead Texas's cautiously optimistic bioinformatics research, dominated by cancer genomics and single-cell transcriptomics with a moderately positive stance.
- The University of Texas MD Anderson Cancer Center127
- The University of Texas Southwestern Medical Center88
- The University of Texas at Austin81
- Texas A&M University78
- The University of Texas Health Science Center at Houston63
- Gene4→28
- Genome1→22
- Transcriptome1→16
- Phenotype1→10
- Immune system1→8
- Disease1→26
- Gene1→14
- Cancer2→13
- Immune system1→12
- Clinical trial1→10
- Disease3→17
- Cancer2→8
- Genome1→5
- Tumor microenvironment1→3
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.